HITI vs MCK vs UPC Stock Comparison

High Tide, Mckesson and Universe Pharmaceuticals Prices as of Oct 29, 2026 Peers: Industry group
HITI High Tide Inc.
$2.66 -5.0% 1M -14.2% 1Y
Market cap
$211.61M
P/E
–
Revenue (TTM)
$520.13M
Div. yield
–
Cannabis Consumer Staples
3 wins
MCK Mckesson Corp
$981.33 +13.5% 1M +21.5% 1Y
Market cap
$118.07B
P/E
25.7x
Revenue (TTM)
$410.98B
Div. yield
0.00%
Drug Distribution Healthcare
7 wins

Head to Head

10 decided of 12

Mckesson leads on 7 of the 12 questions below (Mckesson 7, High Tide 3). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionHITIMCKUPCLeader
Larger companyMarket capitalisation $211.61M $118.07B $20.41M MCK
Cheaper on earningsLower P/E, profitable companies only -8.9x 25.7x — –
Cheaper on forward earningsLower price / next fiscal year consensus EPS 26.6x 20.8x — MCK
Faster revenue growthRevenue growth, trailing twelve months +31.0% +8.8% — HITI
More profitableNet margin, trailing twelve months -4.5% 1.1% — MCK
Better return on capitalReturn on invested capital -1.5% 107.9% — MCK
Less leveragedLower net debt / EBITDA -0.7x 0.6x — HITI
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months -14.2% +21.5% -68.0% MCK
Better 5-year returnAnnualised price return, 5 years -13.4%/yr +36.4%/yr -82.0%/yr MCK
Less volatileAnnualised volatility, 1 year 41.7% 30.8% 209.0% MCK
Higher overall scoreMean of the five percentile scores vs peers 67/100 59/100 — HITI

Percentile Scorecard

HITIMCKUPC

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisHITIMCKUPC
Valuation 76 #10 of 38 54 #12 of 25 –
Growth 65 #13 of 35 65 #9 of 24 –
Profitability 65 #13 of 35 70 #8 of 24 –
Financial Health 64 #14 of 37 48 #14 of 26 56 #288 of 647
Shareholder Returns – 60 #7 of 16 –
Overall 67 59 –
  • HITI ranked among 40 companies in Tobacco and Cannabis
  • MCK ranked among 27 companies in Healthcare Payers and Distributors
  • UPC ranked among 671 companies in Pharmaceuticals and Biotechnology

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodHITIMCKUPCSPY
1 month -5.0%+13.5%-65.9% +0.7%
3 months +24.3%+13.3%-55.7% +3.7%
6 months +9.0%+20.4%-52.3% +7.1%
Year to date +0.4%+19.6%-59.6% +12.8%
1 year -14.2%+21.5%-68.0% +11.9%
3 years +91.4%+118.3%-99.8% +85.2%
3 years, per year +24.2%+29.8%-86.6% +22.8%
5 years -51.3%+372.1%-100.0% +67.6%
5 years, per year -13.4%+36.4%-82.0% +10.9%
10 years —+690.7%— +262.0%
10 years, per year —+23.0%— +13.7%

Risk

MeasureHITIMCKUPCSPY
Volatility, 1Y 41.7%30.8%209.0% 12.7%
Downside volatility, 1Y 40.9%27.4%150.0% 12.6%
Beta vs S&P 500, 1Y 0.93-0.282.22 1.00
Return / volatility, 1Y -0.340.70-0.33 0.94
Max drawdown, 5Y -86.8%-27.2%-100.0% -25.4%
From 52-week high -14.5%-4.7%-87.4% -1.2%
52-week high $3.11$1,030.18$12.18 $779.14
52-week low $2.05$725.17$1.54 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleHITIMCKUPC
P/E now vs peer median -9.2xmedian 16.9x 25.4xmedian 24.3x —median 17.8x
P/S now vs peer median 0.4xmedian 0.9x 0.3xmedian 0.3x —median 9.1x
EV/EBITDA now vs peer median 25.8xmedian 9.8x 16.4xmedian 12.9x —median 15.0x
P/FCF now vs peer median 25.4xmedian 23.9x 17.8xmedian 16.4x —median 21.7x
P/B now vs peer median 2.7xmedian 1.0x -27.0xmedian 2.5x 0.7xmedian 2.2x
PEG now vs peer median -0.45median 0.54 2.12median 1.36 —median 0.35

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsHITIMCKUPC
Revenue $520.13M $410.98B –
Gross profit $135.79M $14.96B –
Operating income -$1.43M $6.50B –
Net income -$23.71M $5.30B –
Free cash flow $9.13M $6.42B –
EPS (diluted) $-0.56 $38.52 –
Cash & equivalents $27.13M $5.16B $27.56M
Total debt $78.40M $9.73B $7.74T
Shares (diluted) 42.43M 119.20M 13.92M
Enterprise value $102.35M $101.97B -$1.50B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricHITIMCKUPC
P/E -9.2x 25.4x –
P/FCF 25.4x 17.8x –
P/Operating cash flow 13.1x 16.7x –
P/S 0.4x 0.3x –
P/B 2.7x -27.0x 0.7x
P/Tangible book 2.7x -13.9x 0.7x
EV/EBITDA 25.8x 16.4x –
EV/EBIT -158.1x 18.3x –
EV/Revenue 0.4x 0.3x –
EV/FCF 24.7x 18.5x –
EV/Operating cash flow 12.7x 17.4x –
PEG (3Y EPS CAGR) -0.45 2.12 –

Growth

14 metrics
MetricHITIMCKUPC
Revenue growth (1Y) 31.0% 8.8% –
Revenue CAGR (3Y) 14.2% 13.1% –
Gross profit growth (1Y) 29.0% 11.2% –
Gross profit CAGR (3Y) 12.5% 6.6% –
Operating income growth (1Y) -205.7% 46.6% –
Operating income CAGR (3Y) 68.6% 13.5% –
Net income growth (1Y) -252.5% 58.1% –
Net income CAGR (3Y) 19.8% 10.7% –
EPS growth (1Y) -243.6% 52.8% –
EPS CAGR (3Y) 20.7% 12.0% –
Operating cash flow growth (1Y) – 4.7% –
Operating cash flow CAGR (3Y) – 10.7% –
Free cash flow growth (1Y) 21.7% 6.8% –
Free cash flow CAGR (3Y) 169.3% 11.3% –

Profitability

14 metrics
MetricHITIMCKUPC
Gross margin 26.1% 3.6% –
EBITDA margin 1.7% 1.8% –
Operating margin -0.3% 1.6% –
Pretax margin 3.5% 1.6% –
Net margin -4.5% 1.1% –
FCF margin 1.8% 1.6% –
Operating cash flow margin 3.4% 1.7% –
Return on equity -29.9% – –
Return on assets -9.3% 6.2% –
Return on invested capital -1.5% 107.9% –
Return on capital employed -0.8% 43.4% –
Asset turnover 2.0x 4.8x –
Cash conversion (OCF / net income) -0.7x 1.3x –
Stock comp / revenue – – –

Financial Health

11 metrics
MetricHITIMCKUPC
Debt / assets 7.9% 11.0% 13.4%
Debt / equity 0.2x -2.3x 0.2x
Net debt / EBITDA -0.7x 0.6x –
Debt / FCF 2.3x 1.5x –
Liabilities / assets 67.5% 104.8% 22.1%
Equity / assets 32.5% -4.8% 77.9%
Interest coverage -0.3x 23.6x –
Current ratio 1.5x 0.9x 4.0x
Quick ratio 0.5x 0.5x 3.8x
Cash ratio 0.4x 0.1x 2.1x
Altman Z-score 1.96 5.90 –

Shareholder Returns

7 metrics
MetricHITIMCKUPC
Dividend yield – 0.3% –
Net buyback yield – 5.8% –
Shareholder yield – 6.1% 0.0%
Payout ratio (earnings) – 7.4% –
Payout ratio (FCF) – 6.1% –
Dividend growth (1Y) – 11.3% –
Dividend CAGR (3Y) – 10.0% –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusHITIMCKUPC
Forward P/E 26.6xFY2026 20.8xFY2026 –
EPS, next fiscal year $0.10FY2026 $47.15FY2026 –
EPS growth, next FY – +20.6%FY2026 –
EPS growth, the year after +10.0% +11.0% –
Revenue, next fiscal year $561.45MFY2026 $444.47BFY2026 –
Revenue growth, next FY +32.5%FY2026 +10.2%FY2026 –
Revenue growth, the year after +12.5% +1.5% –

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersHITIMCKUPC
Held by institutions 8.1% 89.1% –
Institutions holding 47 2,011 –
Change in shares held, QoQ -15.1% -0.7% –
Institutions buying 20 883 –
Institutions selling 15 791 –
Buyers to sellers 1.33 1.12 –

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

HITIMCKUPC
HITI 1.00 -0.11 0.05
MCK -0.11 1.00 -0.12
UPC 0.05 -0.12 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, HITI, MCK and UPC?

Mckesson (MCK) is the largest by market capitalisation: High Tide (HITI) $211.61M, Mckesson (MCK) $118.07B, Universe Pharmaceuticals (UPC) $20.41M.

Which company is growing faster?

High Tide (HITI) grew revenue fastest over the trailing twelve months: High Tide (HITI) +31.0%, Mckesson (MCK) +8.8%.

Which company is more profitable?

Mckesson (MCK) has the highest net margin (High Tide (HITI) -4.5%, Mckesson (MCK) 1.1%). On return on invested capital, Mckesson (MCK) leads (High Tide (HITI) -1.5%, Mckesson (MCK) 107.9%).

Which stock has performed better?

Over the past year Mckesson (MCK) returned the most: High Tide (HITI) -14.2%, Mckesson (MCK) +21.5%, Universe Pharmaceuticals (UPC) -68.0%. Over five years, Mckesson (MCK) compounded fastest (High Tide (HITI) -13.4%/yr, Mckesson (MCK) +36.4%/yr, Universe Pharmaceuticals (UPC) -82.0%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Only one of these companies pays a dividend: High Tide (HITI) 0.00%, Mckesson (MCK) 0.00%, Universe Pharmaceuticals (UPC) 0.00%. High Tide (HITI) and Universe Pharmaceuticals (UPC) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Mckesson (MCK) has been the steadiest (High Tide (HITI) 41.7%, Mckesson (MCK) 30.8%, Universe Pharmaceuticals (UPC) 209.0%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, HITI, MCK and UPC?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Mckesson (MCK) leads on 7. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.